Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries
| Autor: | Helen T Smith, Marian Benroubi, Alexander Simpson, Stephen Jones, Conxa Castell, Marie-Aline Charles, Andreas Liebl, Claudia Nicolay, Albert Goday |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.medical_treatment Type 2 diabetes Bolus (medicine) Diabetes mellitus Internal medicine medicine Humans Hypoglycemic Agents Insulin In patient Prospective Studies Prospective cohort study Aged Glycated Hemoglobin business.industry General Medicine Middle Aged medicine.disease Surgery Europe Clinical trial Diabetes Mellitus Type 2 Female Observational study business |
| Zdroj: | Current Medical Research and Opinion. 27:887-895 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1185/03007995.2011.555755 |
| Popis: | To examine insulin regimens and factors that affect glycaemic control at 6 months after initiation of insulin therapy in patients with type 2 diabetes mellitus.Information on patients requiring insulin initiation as part of usual care was collected in a prospective, observational, open-label study in five European countries. Univariate and multiple regression analyses were used to investigate factors associated with HbA1c achieved at 6 months.Mean HbA1c for all patients at baseline was 9.6 ± 1.8%. Long/intermediate-acting insulin only was most commonly initiated in France and Spain, while long/intermediate or pre-mixed formulations were initiated in Greece and UK. This was consistent with guidelines used in those countries and there was little change in insulin regimen at 6 months in these countries. In Germany, short-acting insulin only was favoured at baseline and there was a shift towards basal/bolus regimens at 6 months, which reflected the local guidelines for insulin initiation in Germany. Mean HbA1c reduction was greatest in Germany (-2.3%), which was the only country to achieve a mean of7% at 6 months. In all countries, HbA1c achieved at 6 months was associated with baseline HbA1c. Differences between countries were seen for influence of factors such as BMI, duration of diabetes, insulin regimen, insulin dose and number of oral anti-diabetes drugs on HbA1c achieved. Explained variability for the factors ranged from 5.6% to 22.9%.Differences in insulin regimen were observed between countries, and appeared to reflect the guidelines and treatment regimens used. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|